Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry News Roundup

This article was originally published in The Tan Sheet

Executive Summary

‘Heal yourself’ claim nicked by FDA; Urban Moonshine’s error of omission; new tech needs old school substantiation; O2 plans big for InboxFitness; Migranade sprouts spray division; ChromaDex cashes in NeutriSci shares; GoodSense sponsors runDisney; Walgreens joins flu tracking crowd; Qualitas algal omega-3 reaches market; Islet cooks cannabidoil in business plan; and Food Advisory Committee candidates sought.

You may also be interested in...



In Brief

Ramirez appointed FTC chair; budget sequester slows FDA travel, training; ChromaDex divests BluScience brand; Omega Protein buys whey firm; Vitamin Shoppe absorbs integration costs; Vitacost trims net loss in Q4; chemical regulation champion Lautenberg to retire; USANA expands in China.

USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities

The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.

ASH Preview: Three Areas To Watch In Hematology-Oncology

Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel